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Abstract
Mitochondrial ferritin (MtF) has been identified as a novel ferritin encoded by an intron-lacking gene with specific
mitochondrial localization located on chromosome 5q23.1. MtF has been associated with neurodegenerative disorders such
as Friedreich ataxia and restless leg syndrome. However, little information is available about MtF in Alzheimer’s disease (AD).
In this study, therefore, we investigated the expression and localization of MtF messenger RNA (mRNA) in the cerebral
cortex of AD and control cases using real-time polymerase chain reaction (PCR) as well as in situ hybridization
histochemistry. We also examined protein expression using western-blot assay. In addition, we used in vitro methods to
further explore the effect of oxidative stress and b-amyloid peptide (Ab) on MtF expression. To do this we examined MtF
mRNA and protein expression changes in the human neuroblastoma cell line, IMR-32, after treatment with Ab, H2O2, or
both. The neuroprotective effect of MtF on oxidative stress induced by H2O2 was measured by MTT assay. The in situ
hybridization studies revealed that MtF mRNA was detected mainly in neurons to a lesser degree in glial cells in the cerebral
cortex. The staining intensity and the number of positive cells were increased in the cerebral cortex of AD patients. Real-
time PCR and western-blot confirmed that MtF expression levels in the cerebral cortex were significantly higher in AD cases
than that in control cases at both the mRNA and the protein level. Cell culture experiments demonstrated that the
expression of both MtF mRNA and protein were increased by treatment with H2O2 or a combination of Ab and H2O2, but
not with Ab alone. Finally, MtF expression showed a significant neuroprotective effect against H2O2-induced oxidative
stress (p,0.05). The present study suggests that MtF is involved in the pathology of AD and may play a neuroprotective role
against oxidative stress.
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Introduction
We and others have previously shown that iron and iron
regulatory proteins are involved in the pathology of Alzheimer’s
disease (AD). Postmortem examinations of human brain tissue
have demonstrated that iron concentrations are increased in the
brains of AD patients compared to controls [1,2,3]. Iron [1,4,5]
and iron regulatory proteins such as ferritin [3], transferrin [3,6],
melanotransferrin [6] and lactoferrin [7,8] have been detected in
senile plaques and/or neurofibrillary tangles, reportedly major
sites for catalytic redox activity [9]. Excessive iron deposition may
generate some of the oxidative stress know to occur in AD
[4,9,10,11,12].
Mitochondria havea key role in ironmetabolismbecause theyare
involved in synthesizing heme and various iron-sulfur (Fe-S) cluster-
containing proteins [13,14]. The last step in heme biosynthesis, the
insertion of Fe
2+ into protoporphyrin IX by ferrochelatase, occurs in
the mitochondrial matrix [13]. Mitochondrial iron levels must be
well regulated because an inadequate supply of iron would impair
the metabolic and respiratory activities of the organelle [14,15,16],
while excess ‘‘free’’ iron in mitochondria would promote the
generation of harmful reactive oxygen species which may cause
diseases such as sideroblastic anemia [15].
Recently, mitochondrial ferritin (MtF) has been identified as a
novel ferritin encoded by an intronless gene on chromosome
5q23.1. This gene product has been localized to the mitochondria
in humans [17]. MtF is expressed as a 30-kDa precursor that is
targeted to mitochondria by a positively charged leader sequence.
Proteolysis of the N-terminal leader sequence within the
mitochondria forms a 22-kDa MtF subunit, which has high-
sequence homology to H-type ferritin, including conservation of
the ferroxidase center and activity [18,19]. MtF has been detected
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spleen, but levels are high in the testes in which mitochondria are
abundant [19,20]. The distribution pattern of MtF suggests that
MtF may play an important role in mitochondrial function.
The function of MtF has not been elucidated. However, several
studies have implicated MtF in a number of neurological disorders
such as Friedreich ataxia [21] and restless legs syndrome [22].
Although abnormalities of mitochondrial function and iron
metabolism have been reported in AD, little information is
available about MtF in the brains of AD patients. In this study,
therefore, we investigated the expression and localization of MtF
messenger RNA (mRNA) in the cerebral cortex of AD and control
cases using real-time polymerase chain reaction (PCR) and in situ
hybridization histochemistry. We also examined MtF protein
expression in AD patient brain tissues using a western-blot assay.
In addition, we examined the effect of b-amyloid peptide (Ab 1–
42) and H2O2 treatments on the expression of MtF mRNA and
protein in a human neuroblastoma cell line, IMR-32. The
neuroprotective effect of MtFt against oxidative stress induced
by H2O2 was also examined.
Materials and Methods
Ethics statements
Human brain tissues were obtained from the Brain Donation
Program at the Banner Sun Health Research Institute [23].
Written informed consent was obtained from all donors or their
legal representatives. The Brain Donation Program has been
approved by the Institutional Review Board of the Banner Health
Corporation. The study was also approved by the ethics
committee at Shiga University of Medical Science.
Brain samples
Total RNA and protein were purified from the temporal cortex
and cerebellum of eight sporadic AD cases (mean age 6 S.D.,
82.369.2 years) and eight control cases without neurological
disease (mean age 6 S.D., 85.169.7 years). Brain tissue from
another three AD cases (mean age 6 S.D., 83.363.8 years) and
three control cases (mean age 6 S.D., 73.7613.0 years) were used
for in situ hybridization. For Western blots, brain tissue from three
AD cases (mean age 6 S.D., 80.769.0 years) and three control
cases (mean age 6 S.D., 79.067.1 years) was used. The average
postmortem delay for the AD and control cases was 2.62 and
2.71 hours, respectively.
In situ hybridization
Human MtF cDNA was obtained from the plasmid, pCMV6-
XL5 (OriGene Technologies, Inc., Rockville, MD). The entire
MtF coding region was inserted into the pGEM-T Easy vector
(Promega, Madison, WI, USA) by PCR using the following
primers: 59-GAACAGGACGACTGGGAAAGCG-39; and 59-
AGAGCGTGCAATTCCAGCAACG-39. After linearization with
SacII and SalI, digoxigenin-UTP labeled sense and antisense
riboprobes were transcribed using SP6 and T7 RNA polymerases
according to the manufacturer’s protocols. The riboprobes were
subsequently purified by ethanol precipitation.
In situ hybridization was used to examine MtF mRNA
expression in the temporal cortices from three AD cases and
three control cases. The tissue was processed following previously
described methods [24,25,26]. Sections were treated for 10 min at
room temperature with 10 mg/ml proteinase K in 10 mM Tris-HCl
buffer (pH 8.0) containing 150 mM NaCl at 37˚C, and then post-
fixed with4%paraformaldehydein0.1 MPBSatroomtemperature
for 10 min. Sections were pre-hybridized for 2 h at 37˚Ci n
hybridization buffer (50% formamide, 5 x Denhardt’s solution, 3 x
saline/sodium citrate (SSC; 1x: 150 mM NaCl and 15 mM sodium
citrate), 0.5 mg/ml yeast tRNA (Gibco BRL), and 0.5 mg/ml heat-
denatured salmon sperm DNA (Wako Pure Chemicals Co., Osaka,
Japan). Probes were diluted in hybridization buffer to a final
concentration of 2 mg/ml and hybridized for 16 h at 60˚C. After
hybridization, the sections were washed briefly in pre-warmed 3 x
SSC at 60˚C, then rinsed for 2 h in pre-warmed 0.2 x SSC buffer at
60˚C. Sections were then rinsed for 5 min in NT buffer (0.1 M Tris
HCl, pH 7.5 and 150 mM NaCl ) at room temperature. Sections
were blocked in 1% skim milk in NT buffer for 60 min, and
incubated overnight at 4˚C with alkaline phosphatase-labeled anti-
digoxigeninantibody(1:200;RocheDiagnostics,Basel,Switzerland).
After washing with NT buffer, signal was detected using the
substrates nitroblue tetrazolium chloride (NBT) and 5-bromo-4-
chloro-3-indolylphosphate p-toluidine salt (BCIP).
Preparation of Ab oligomers
We used Ab-derived diffuse ligands (ADDLs) as typical Ab
oligomers. ADDLs are a mixture of Ab oligomers including SDS-
resistant 3–24 mers of Ab [27,28,29,30,31]. ADDLs are widely
used for AD research as they display neurotoxicity and have been
detected in the cerebrospinal fluid of Alzheimer’s patients [32].
Ab oligomers were prepared as described previously [33,34].
Briefly, synthetic Ab 1–42 peptide (Peptide Institute, Osaka, Japan)
was dissolved in HFIP to 1 mM and incubated for 1 hour at 37uC.
After incubating on ice for 15 min, the HFIP was then removed by
evaporation and the resulting peptide was stored at 220uC. Before
use, the peptide film was re-suspended to 5 mM in dimethyl
sulfoxide (DMSO) [35] followed by sonication for 15 min. Ab 1–42
oligomers were prepared by diluting the solution in DMEM/Phenol
Red-free Ham’s F-12 medium without glutamine to a final
concentration of 100 mM and then incubating for 24 h at 4uC
[36]. The preparation was centrifuged at 16,0006g for 10 min at
4uC to remove insoluble aggregates, and the supernatant containing
soluble oligomers was transferred into clean tubes. These prepara-
tions were used directly for cell treatments. The concentration of Ab
oligomers wasdetermined using a Bio-Radprotein dye assay reagent
(Hercules, CA, USA). A final concentration of 15 mM was used for
cell treatment. Formation of Ab oligomers was determined by silver
staining and examination by electron microscope.
Silver staining of Aß oligomers
Samples were diluted at 1:2 with Tricine sample buffer (Bio-rad
Laboratories, Hercules, CA) and were not heated before loading.
Five microliters of each sample was run on a 15–20% precast
polyacrylamide Tris-Tricine gel (Supersep Tricine gel; Wako,
Osaka, Japan). After electrophoresis, the gel was stained using a
silver staining kit (Nacalai Inc., Osaka, Japan).
Electron microscopy examination for Aß oligomer
formation
Two microliters of each sample was adsorbed onto a carbon-
and Formvar-coated copper grid (200-mesh) by floating on a drop
of sample solution. After washing with distilled water, the sample
on the grid was negatively stained with 2% aqueous uranyl acetate,
and then dried. Samples were then observed under a transmission
electron microscope (H-7600; Hitachi, Japan) at 80 kV.
Cell culture and treatment with ADDL, H2O2 and
peroxynitrite
A human neuroblastoma cell line (IMR-32, purchased from
ATCC, CRL-2468, Manassas, VA, USA) was used in this study.
Mitochondrial Ferritin in Alzheimer’s Disease
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supplemented with 10% fetal bovine serum (FBS), 1% Sodium
pyruvate (Sigma, St. Louis, MO, USA), 1% L-glutamine (Sigma,
St. Louis, MO, USA) and 1% penicillin/streptomycin (Nacalai
Inc., Osaka, Japan) at 37uC in a humidified atmosphere of 5%
CO2 and 95% air.
Three different treatments were investigated using IMR-32 cells
cultured in 12-well plates: 1) treatment with 15 mMA b oligomers
for 24 h; 2) treatment with 300 mM hydrogen peroxide H2O2,
diluted from 30% hydrogen peroxide solution (Santoku Chemical
Industries Co., LTD, Japan), for 30 min; 3) treatment with both
15 mMA b and 300 mM H2O2, and, 4) treatment with 10 mM
peroxynitrite (WAKENYAKU Co., LTD, Japan) for 24 hours as a
second method of inducing oxidative stress [37]. Peroxynitrite
concentration was determined spectrophotometrically at 302 nm
in 0.1 M NaOH (a ˚302 nm=1670/M per cm). Decomposed
peroxynitrite was obtained by incubating peroxynitrite in complete
medium for 30 min at room temperature. For a negative control,
cells were treated with an equal amount of DMSO to that used
during preparation of the Ab oligomers. Cells were subsequently
incubated for a further 18 h before being assessed for viability or
other end point measures. All experiments were performed in
triplicate.
Real-time PCR for human AD brain and in vitro
experiments
MtF mRNA was detected by real-time PCR using a Light
Cycler system (Roche Diagnostics K.K., Tokyo, Japan). The sense
primer was 59- GCTCTATGCGTCCTACGTGTACTTGT-39,
and the antisense primer was 59-TCCTGTTCCGGCTTCTT-
GAT-39. Real-time PCR analysis for b-actin mRNA was also
employed to assess the variability of mRNA content. The results
were analyzed using the LightCycler Software second derivative
maximum method (Roche Diagnostics). Relative quantification of
mRNA was performed based on fluorescence measurements in
comparison with a standard curve that was generated during the
course of each PCR run: values were normalized to the b-actin
mRNA levels in each sample. All experiments were performed
independently at least three times. For the in vitro experiments, the
detection of MtF mRNA expression by real-time PCR was the same
as for the human AD brain real-time PCR assay as described above.
Statistical significance was assessed using the one-way ANOVA test.
Significance was set at p,0.05.
Western-blot analysis of MtF
Human brain samples for western-blot were collected and
treated as previously described [8]. Cells were lysed with RIPA
buffer (50 mM Tris [tris (hydroxymethyl) aminomethane]-HCl,
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate,
and 0.1% sodium dodecyl sulfate [SDS]). Protein content was
determined using the Bio-Rad protein dye assay reagent (Hercules,
CA, USA). Lysates containing equal amounts of protein were
heated for 3 min at 95uC in Laemmli loading buffer and resolved
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). They
were then transferred to a polyvinylidene difluoride membrane
(Immobilon-P, Nippon Millipore Ltd., Tokyo, Japan). BioRad
molecular weight markers (Precision Plus, Nippon BioRad
Laboratories, Tokyo, Japan) were used. The blots were blocked
by incubation for 1 hour with 5% nonfat milk in Tris-buffered
saline (TBS) containing 0.1% Tween 20 (TBST) and were
hybridized overnight at 4uC with anti-MtF rabbit polyclonal IgG
1:1000 (A93251Hu, Uscn, Wuhan, China), or anti-actin mouse
monoclonal IgG 1:1000 (MAB1501, Chemicon International Inc.,
Billerica, MA, USA). After washing 3 times for 10 minutes each
with TBST, the blots were incubated for 1 hour with horseradish
peroxidase-linked anti-rabbit IgG 1:10,000 (ImmunoPure, Pierce,
Rockford, USA). After extensive washing with 25 mM TBST,
labeling was visualized by chemiluminescence using ECL western
blotting detection reagents (SuperSignal West Pico, Thermo
Scientific, Rockford, IL).
Transfecting the MtF-expressing plasmid into IMR-32
cells
The entire coding region of MtF was subcloned into the pGEM-
T Easy vector as mentioned above. This produced a plasmid
containing a 768-bp fragment which encompassed the entire
human MtF sequence, and included a SalI site at the 59 end and a
SacII site downstream of the stop codon at the 39 end of the MtF
gene. The 768-bp SalI/SacII insert was excised and subcloned into
the SalI/SacII site of the pEGFP-N1 expression vector (CLON-
TECH Laboratories, Inc., Palo Alto, CA). Correct constructs were
confirmed by sequencing.
IMR-32 cells were transiently transfected with the expression
construct using the FuGENE HD transfection reagent (Roche
Diagnostics, Mannheim, Germany). Briefly, 5610
5 or 1610
4 cells
were plated on 60 mm dishes or on 96-well plates respectively and
transfected according to the manufacturer’s instructions. Cells
were maintained in modified Eagles medium (MEM) supplement-
ed with 10% fetal bovine serum (FBS), 1% Sodium pyruvate
(Sigma, St. Louis, MO, USA), 1% L-glutamine (Sigma, St. Louis,
MO, USA) in a humidified atmosphere (5% CO2, 95% air) at
37uC. Experiments were performed 24 h after transfection and
protein expression after transfection was detected using western-
blotting.
Assessment of cell viability
Culture cells were transfected as described above. Twenty-four
hours after transfection, the medium was replaced with fresh
medium with or without 300 mMH 2O2 and incubated for 30 min.
Cells were subsequently incubated in fresh medium for a further
18 h before being assessed for viability. Cell viability was measured
by MTT assay. Briefly, MTT (500 mg/ml, Bioassay Systems,
Hayward, CA, USA) was added to each well and incubated for 4 h
at 37uC. The medium was aspirated and cells were lysed with
DMSO. The absorbance at 570 nm was measured with a TECAN
infinite M200 microplate reader (TECAN, Austria). Each
experiment was repeated three times. Statistical significance was
assessed using the one-way ANOVA test. Significance was set at
p,0.05.
Results
In situ hybridization histochemistry
Figure 1 shows the results of in situ hybridization histochemistry
in the temporal cortex of a control (Fig. 1A, B, C) and an
Alzheimer (Fig. 1D, E, F) case. Positive signals for MtF mRNA
were detected in both control (Fig. 1 A) and AD (Fig. 1D) cases
using the antisense probe. At a high magnification, positive signals
were localized predominantly in neurons (Fig. 1E). The staining
intensity in MtF-positive neurons was increased in AD cases
(Fig. 1E) compared to controls (Fig. 1B). The sense probe did not
generate any signal (Fig. 1C and F).
Real-time PCR analysis using total RNA from human brain
Real-time PCR was used to compare the expression levels of
MtF mRNA between AD and control cases (Fig. 2). When
normalized to ß-actin, the mean expression levels of MtF mRNA
in temporal cortex of control and AD cases were 0.02360.003
Mitochondrial Ferritin in Alzheimer’s Disease
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respectively. The mean expression levels of MtF mRNA in the
cerebellum of control and AD cases were 0.02460.008 (mean 6
SEM, n=8) and 0.03960.002 (mean 6 SEM, n=8), respectively.
MtF mRNA levels in AD temporal cortices were significantly
increased to 326% of control levels (P,0.01). There was no
significant difference in MtF expression in the cerebellum between
AD cases and controls.
Determination of Ab oligomer formation
Supernatant proteins were separated on a Tris tricine gel using
SDS-PAGE and visualized with a silver stain. SDS-PAGE analysis
of oligomeric preparations before the 24-h incubation period
showed no oligomeric species except for monomers (Fig. 3A; 0 h).
After the 24-h incubation period, high molecular weight species
between 17 and 25 kDa were apparent (Fig. 3A; 24 h). In these
images, the uniform gray background is due to the silver staining
process.
In addition, small and sparsely distributed spherical structures
were detected by EM analysis after the 24-h incubation period
(arrowheads in Fig. 3B).
Real-time PCR analysis using total RNA from culture cells
Figure 4 A shows the results of real-time PCR analysis of MtF
mRNA using total RNA from cultured cells in the H2O2
treatment group, the Ab treatment group, the H2O2 plus Ab
treatment group, as well as the two control groups: DMSO treated
and untreated cells. The MtF mRNA expression level was not
changed by Ab treatment but was significantly increased by H2O2
treatment (P,0.01). The results indicate that oxidative stress
induces MtF expression in IMR32 cells. When Ab neurotoxicity
was added to oxidative stress, the expression of MtF mRNA was
significantly accelerated. The MtF mRNA expression level in the
combination group was the highest of all five groups (p,0.01
compared to control groups and p,0.05 compared to H2O2
treatment). DMSO treated groups showed no significant change in
MtF expression.
Figure 4 B shows the results of real-time PCR analysis of MtF
mRNA using total RNA from cultured cells in the peroxynitrite
Figure 1. In situ hybridization histochemistry of the cerebral cortex of control (A–C) and Alzheimer’s disease (AD) cases (D–F) using
antisense (A, B, D, E) and sense (C, F) probes. Mitochondrial ferritin mRNA localizes mainly in neurons. Both the number and intensity of
positive neurons increase in AD cases (D) compared to controls (A). Using sense probes (C and F), no signals are detected in the cortex. Bars =200 mm
in A, C, D, F, and 50 mmi nB ,E .
doi:10.1371/journal.pone.0022325.g001
Figure 2. The expression levels of mitochondrial ferritin mRNA
in the cerebral cortex of control and Alzheimer’s disease (AD)
patients and control cases. The expression in the temporal cortex
(TC) of AD patients is significantly higher compared to that in control
cases and cerebellum (Ce). Asterisk indicates significantly different to
control (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0022325.g002
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expression level was not changed significantly by peroxynitrite
treatment. Neither the NaOH vehicle (0.3 M) nor the peroxyni-
trite decomposition products had a significant effect on MtF
mRNA expression.
Western blotting analysis of MtF
Figure 5 shows a western-blot analysis of MtF expression in
human brain. The expression levels of MtF in the temporal cortex
of AD patients (Fig.5 A, A) are higher than in control cases
(p,0.05, Fig. 5 A, C).
Figure 6 shows the western-blot analysis of MtF protein
expression in the H2O2 treatment group, the Ab treatment group,
the H2O2 plus Ab treatment group, as well as the two control
groups: DMSO treated and untreated cells. MtF protein
expression after treatment with H2O2 or a combination of Ab
and H2O2 was significantly higher than in control groups. The
combination group showed the highest MtF protein expression
level of all groups. However, single treatment with Ab or DMSO
caused no significant effect on MtF protein expression. These
results are in accordance with the real-time PCR results.
MtF expression significantly rescues cell death after H2O2
treatment
In order to investigate the possible roles of MtF in neuropro-
tection, wild type IMR-32 cells (IMR-32), empty vector transfec-
tants (vector-IMR-32) and MtF transfectants (MtF-IMR-32) were
incubated with or without 300 mMH 2O2 for 30 min. Figures 7A
and B show the results of cell viability and western blots of MtF,
respectively. Similar to previous reports [15,17,18], an MtF
protein band with an apparent molecular mass of 22 kDa was
detected by SDS-PAGE. Weak bands were detected in IMR-32
and vector-IMR-32 cells (Fig. 7B). A remarkable decrease in the
viability of IMR-32 and Vector-IMR-32 cells (about 50%; p,0.01,
compared with the control groups) was observed after treatment
with 300 mMH 2O2 for 30 min (Fig. 7A). The viability of MtF-
IMR-32 cells decreased about 30% after H2O2 treatment,
therefore cell viability was much higher than in control groups
(p,0.05). These results show that overexpression of MtF reduces
the rate of cell death after H2O2 treatment.
Figure 3. Formation of oligomeric Ab1–42 assemblies. (A)
Profiles of Ab1–42 oligomers before (0 h) and after 24-h incubation
(24 h) on SDS-PAGE followed by silver staining. M: Molecular weight
markers. 0 h: Ab1–42 preparation 0 h at 4uC. 24 h: Initial ADDL
preparation 24 h later at 4uC. (B) Electrophoretic pattern of Ab1–42
oligomeric preparations separated with centrifugal filters before
electrophoresis. Representative photographs showing Ab1–42 prepa-
rations before (0 h) and after incubation (24 h). Arrowheads in B
indicate Ab1–42 oligomers. Scale bar: 50 nm.
doi:10.1371/journal.pone.0022325.g003
Figure 4. Mitochondrial ferritin mRNA expression levels in cultured cells. (A) Compared to the control, the MtF mRNA expression level is
significantly high after H2O2 treatment but not after treatment with Ab or DMSO. The group treated with both of H2O2 and Ab displays the highest
level of MtF mRNA expression among all groups. Asterisks and double asterisks indicate p,0.05 and p,0.01, respectively. (B) Results of real-time PCR
analysis of MtF mRNA using total RNA from cultured cells in the peroxynitrite treatment group and the control groups. The MtF mRNA expression
level was not changed significantly by peroxynitrite treatment.
doi:10.1371/journal.pone.0022325.g004
Mitochondrial Ferritin in Alzheimer’s Disease
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Using in situ hybridization histochemistry, we first demonstrated
that MtF mRNA was localized predominantly in neurons in the
temporal cortex of the human brain in both control and AD cases.
Neuronal localization of MtF mRNA is in accordance with
previous reports concerning localization of MtF protein in human
substantia nigra [22] and mouse brain [20]. Interestingly, we
demonstrated that the MtF mRNA signal intensity appeared to be
increased in AD brains. In agreement with the in situ results, the
quantitative PCR and western blot experiments showed that MtF
mRNA and protein levels were increased in the temporal cortex of
AD brains compared to controls. These results suggest that MtF
may be involved in pathological processes in AD. More cases will
be investigated in future studies to provide stronger evidence for a
role of MtF in the progression of AD.
The cell culture experiments demonstrated that the expression
of MtF was not altered by Ab neurotoxicity or peroxynitrite
treatment but was increased by H2O2 treatment. Peroxynitrite
produces nitric oxide (NO) and can induce oxidative stress.
However, treatment with peroxynitrite did not alter MtF
Figure 6. Western-blot analysis of MtF expression in each in
vitro experiment group. (A) An immunoreactive band of approxi-
mately 22 kD probed with an anti-MtF antibody is present in all lanes.
(B) When the expression level of MtF is normalized to b-actin, MtF
expression after treatment with H2O2 or with a combination of Ab and
H2O2 was significantly greater than that in control cases (**p,0.01.
*** p,0.001). However, treatment with Ab or DMSO alone shows no
significant effect on MtF expression.
doi:10.1371/journal.pone.0022325.g006
Figure 5. Western-blot analysis of MtF expression in human
brain. (A) Three AD cases (lanes marked A) and three control cases
(lanes marked C) were probed with anti b-actin antibody and anti MtF
antibody. (B) When the expression level of MtF is normalized to b-actin,
the expression level of MtF in the temporal cortex of AD patients is
higher than in control cases (**p,0.01).
doi:10.1371/journal.pone.0022325.g005
Figure 7. Effect of MtF expression on cell viability after
treatment with H2O2. An MtF protein band exists with an apparent
molecular mass of 22 kDa on SDS-PAGE; weak bands were detected in
IMR-32 and vector-IMR-32 cells (B). Wild-type IMR-32 cells, empty vector
transfectants (Vector-IMR-32), and MtF transfectants (MtF-IMR-32) were
treated with 300 mMH 2O2 for 30 min (A). Cell viability was measured by
MTT assay. A remarkable decrease in the viability of IMR-32 and Vector-
IMR-32 cells (about 50%; p,0.01, compared with control groups) was
observed after treatment with 300 mM H2O2 for 30 min (A). The viability
of MtF- IMR-32 cells under treatment decreased about 30%, however,
the cell viability was much higher than in the control group (p,0.05).
** p,0.01 vs. non-treated cells; *p ,0.05 vs. the H2O2-treated control
cells.
doi:10.1371/journal.pone.0022325.g007
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increase in MtF expression may be specific to H2O2-induced
oxidative stress. H2O2, a reactive oxygen species, is a by-product
of normal cellular function and is produced by superoxide
dismutase (SOD) and monoamine oxidase (MAO). Normally,
H2O2 is broken down in brain by the actions of glutathione
peroxidase and catalase; however, under certain pathophysiolog-
ical conditions where excessive H2O2 is produced, cellular
defenses can be overwhelmed and H2O2 may then provoke
oxidative stress [38].
Interestingly, the present study demonstrated that MtF mRNA
and protein expression were increased most by the combination of
H2O2 and Ab. However, there were no differences between Ab
treatment and the control group in terms of MtF mRNA and
protein expression levels. Several previous studies have suggested a
relationship between Ab and oxidative stress induced by iron. It
has been demonstrated that iron can facilitate the aggregation of
Ab and increase its toxicity [39,40]. Iron has also been shown to
induce the aggregation of hyperphosphorylated t (tau), the major
constituent of neurofibrillary tangles [5] and has been associated
with senile plaques and neurofibrillary tangles in human AD
brains [1,4,5]. Furthermore, it has been suggested that excessive
iron can generate oxidative stress in AD [4,9,10,11,12].
The precise role of MtF in AD still remains unknown. However
this and previous studies have raised several possibilities. Since
Fe
2+ displays a toxic effect on cells, the increased Fe
2+ in AD brain
tissues may be a cause of neuronal damage. In addition, Fe
2+ can
enhance the formation of Ab oligomers and senile plaques [39,40].
Because MtF has high-sequence homology to H-ferritin, including
conservation of the ferroxidase center and activity [18], MtF is
thought to oxidize the potentially toxic ferrous iron. In addition,
MtF can reduce iron concentration in the cytoplasm. MtF has a
positively charged leader sequence that provides it with a means to
access the mitochondria [38]. Overexpression of MtF can draw
iron from the cytosolic iron pool to the mitochondria and reduce
cellular iron concentration [41,42,43]. Based on our in vitro results,
it is likely that MtF may prevent cell injury and tissue damage, and
therefore protect brain integrity, through antioxidant functions.
The neuroprotective effect of MtF is supported by the culture
experiments showing that the overexpression of MtF decreased
IMR-32cell death. However, even though there is an endogenous
increase in MtFt upon incubation with H2O2, there is no rescue of
cell viability in the same cells unless MtFt is expressed before
H2O2 is added to the cells. This may be because H2O2-induced
cell death occurs before MtFt can have its neuroprotective effect.
Therefore, it appears that the MtF which is overexpressed before
H2O2 addition has a greater protective effect than the endogenous
MtF. Further study is needed to clarify this issue.
In summary, the present study has shown that MtF mRNA
locates mainly in neurons and its expression is up-regulated in the
cortex of AD patients. We have also demonstrated, through in vitro
experiments, that this increase in MtF expression may be induced
by H2O2-provoked oxidative stress rather than by Ab. Moreover,
MtF overexpression has a neuroprotective effect against oxidative
stress induced by H2O2. These results indicate that MtF may be
involved in the pathological process of AD.
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